Company profilePharmaceutical#331 of 1,318 in Pakistan✓ No DRAP alerts

APTCURE PRIVATE LIMITED

Pharmaceutical company · 53 brands · 58 molecules

53 registered products 30 pharmaceutical brands 58 distinct molecules 0 DRAP alerts

Company overview

53
registered products
30
pharmaceutical brands
58
distinct molecules
0
therapeutic classes
0
DRAP alerts

APTCURE PRIVATE LIMITED is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 53 product registrations across 58 distinct molecules. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by APTCURE

24 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

24
ceilings with an approval date
0
not revised in 2+ years
2026
oldest approval year
202624

Top molecules by brand count

Risperidone4 brands
Cefixime3 brands
Azithromycin3 brands
Entecavir3 brands
Bisoprolol2 brands
Omeprazole2 brands
Moxifloxacin2 brands
Levofloxacin2 brands

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official47 products · Rs 171.61 – Rs 10,420.89
Median across source: Rs 397.77

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

BIO LABS (PVT) LTD.28 shared molecules
NEUTRO PHARMA (PVT) LTD.25 shared molecules
HIGH - Q INTERNATIONAL22 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

GENOME PHARMACEUTICALS (PVT) LTD holds 99 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtemether
GETZ PHARMA PAKISTAN (PVT) LTD. holds 260 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
BIO LABS (PVT) LTD. holds 125 molecules not in this portfolio
000 I.UAmlodipineAprepitantAremetherArtemetherArtesunate

Get the full profile for APTCURE

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.